Lyell Immunopharma Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Lyell Immunopharma Inc
Access all reports
Lyell Immunopharma Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. It develops BioPulse treatment which modulates the expression of tumor antigens to amplify cellular immunotherapy. The company offers B-chimeric antigen receptor (CAR) to stimulate infiltration of T cells into cancer cells. Its cytokine treatments include OncoPuls, which aims at generating self-amplifying CAR populations expressing a single target antigen; and UniPuls, which has the potential to express multiple antigens and can be used with conventional chemotherapy formulations. Its other product is intratumoral T cell vaccines, which targets epithelial cancers. The company utilizes its proprietary technologies in the development of novel therapeutics for the treatment of antibody-refractory cancers. It also focuses on the discovery and development of programmable immune cell therapies using Autologous Dendritic Cells (DCs) and T cells; Identification of Biotherapeutics for Cancer; Antibody Directed Selection/Activation of T Cells (ADSTAT); and Novel Cancer Therapeutic Products Development Platforms.
Key slides for Lyell Immunopharma Inc
J.P. Morgan 42nd Annual Healthcare Conference 2024
Lyell Immunopharma Inc
J.P. Morgan 42nd Annual Healthcare Conference 2024
Lyell Immunopharma Inc
Latest articles
Daniel Ek: Co-founder and CEO of Spotify
Explore Daniel Ek's journey from a tech-savvy teenager to the co-founder and CEO of Spotify and the most influential person in the music industry.
28 Mar 2024
Companies That Had Their IPO in 1992: A Cautiously Optimistic Market
1992 marked a relatively cool IPO landscape and stock market sentiment, in the wake of the early 90s recession.
28 Mar 2024
Remembering Daniel Kahneman: Transforming Psychology and Economics
Explore Daniel Kahneman's legacy in psychology and economics, highlighting his impact on decision-making and behavioral economics.
28 Mar 2024
Ticker symbol
Country
🇺🇸 United States